ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether TOK-001 is safe and shows biological effect
in the treatment of castration resistant prostate cancer (CRPC).